---
schema_version: "secwatch.filing_event.v1"
accession: "0001785530-22-000020"
form_type: "8-K"
ticker: "HOWL"
cik: "0001785530"
company_name: "Werewolf Therapeutics, Inc."
filed_at: "2022-05-10T23:59:59+00:00"
generated_at: "2026-06-25T21:53:44.903547+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Werewolf Therapeutics Q1 net loss $15.3M; Jazz Pharma license and $40M loan extend runway

## Summary
- Net loss of $15.3M in Q1 2022 vs. $7.4M year-ago; R&D expense rose to $10.9M from $4.8M.
- Cash and equivalents of $143.7M at March 31, 2022; plus Jazz $15M upfront and $20M loan tranche, runway through Q4 2023.
- Entered exclusive global license with Jazz for WTX-613; $15M upfront, up to $1.26B milestones plus mid-single-digit royalties.
- IND submissions for WTX-124 and WTX-330 on track; preclinical data presented at AACR 2022.
- Closed $40M term loan with Pacific Western Bank; $20M available upon two IND acceptances by March 31, 2023.

## SEC filing metadata
- accession: 0001785530-22-000020
- form_type: 8-K
- ticker: HOWL
- cik: 0001785530
- company_name: Werewolf Therapeutics, Inc.
- filed_at: 2022-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1785530/000178553022000020/0001785530-22-000020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1785530/000178553022000020/howl-20220510.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001785530-22-000020
- JSON: https://secwatch.observer/filing/0001785530-22-000020.json
- Plain text: https://secwatch.observer/filing/0001785530-22-000020.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.